Title: Dual Src and EGFR Inhibition in Combination with Gemcitabine in Advanced Pancreatic Carcinoma: Phase I Results

Journal Name: Investigational New Drugs

Authors: Dana B. Cardin, MD 1,2, Laura W. Goff, MD 1,2, *Emily Chan, MD, PhD 3, Jennifer G. Whisenant, PhD 1,2, G. Dan Ayers, MS 4,5, Naoko Takebe, MD, PhD 6, Lori R. Arlinghaus, PhD 7, Thomas E. Yankeelov, PhD 8, Jordan Berlin, MD 1,2, Nipun Merchant, MD 9

1Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA
2Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
3Amgen Inc., Thousand Oaks, CA, USA
4Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA
5Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN, USA
6Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
7Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN, USA
8Institute for Computational and Engineering Sciences, Departments of Biomedical Engineering and Diagnostic Medicine, Livestrong Cancer Institutes, University of Texas, Austin, TX, USA
9Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, USA

Please address correspondence to:
Dana B. Cardin, MD
dana.cardin@vanderbilt.edu

Supplemental Figure 1: CA19-9 levels correlate with changes in tumor size. Moderate and significant positive correlation (Pearson Correlation = 0.65, p=0.023) observed between changes in CA19-9 levels at four weeks and tumor size at eight weeks.